Japan's Central Social Insurance Medical Council, which advises the health minister, approved public health insurance coverage for donanemab, an Alzheimer's medicine developed by U.S. drugmaker Eli Lilly. https://www.japantimes.co.jp/news/2024/11/13/japan/science-health/insuarance-coverage-alzheimers-drug/ #japan #sciencehealth #alzheimer039s #pharmaceuticals #donanemab #nationalhealthcare #mentalhealth #dementia #medicine